{
  "doc_id": "Relatório de avaliação de financiamento público  de Lumykras (sotorasib)",
  "created_date": "2015",
  "country": "PT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "Introduction",
      "text": "INFARMED, I.P.  Direcção de Avaliação das Tecnologias de Saúde (DATS) RELATÓRIO PÚBLICO DE AVALIAÇÃO LUMYKRAS (SOTORASIB) Tratamento de doentes adultos com cancro do pulmão de não pequenas células (CPNPC) advanced with KRAS G12C mutado e que tenham progredido após, pelo menos, a line de terapêutica sistémica previa à Avaliação do financiamento ao abrigo do Decreto -Lei n.o 97/2015, de 1 de junho, na sua redação atual.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "2",
      "text": "Lumykras (Sotorasib) 2 M-DATS -020/4 DATA DAY OF DECISION OF INDEFERIMENTO: 28/06/2024 CHARACTERÍSTICAS DO MEDICAMENTO: DCI (common international denomination): Sotorasib Name of the medicinal product: Lumykras Apresentação: Sotorasib  240 Unidades, comprimido revestido por película , 120 mg , registo n.o 5832027 Titular da AIM: Amgen Europe, B.V. SUMÁRIO DA AVALIAÇÃO RESUMO DA AVALIAÇÃO FARMACOTERAPÊUTICA: O medicamento Lumykras (Sasib) has been subject to a prior evaluation for public financing effects on the treatment of non-cancer patients with small cell carcinoma (CPC) and has been shown to have no prior treatment of the disease, in comparison to the treatment of cancer cells of the face, or to the treatment of cancer cells of the face, or to the treatment of cancer of small blood cells of the face, or",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "3",
      "text": "Epidemiology and Characterization of Disease Pulmonary cancer is a disease of natural origin but not yet diagnosed worldwide (excluding as neoplasms cut from non-melanocytes) and is a leading cause of death from natural causes worldwide. Globally, only 18% of the population will be alive for 5 years or more after diagnosis.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "4",
      "text": "Lumykras (Sotorasib) 4 M-DATS -020/4 2. Description of the technology and therapeutic alternatives LUMYCRAS (sotorasib) is a covalent and irreversible inhibitor at the level of the KRAS G12C system. An inativa due to the KRAS G12C by the sotorasib blocks a signal, inhibits growth and promotes a selective apoptosis in tumors carrying the KRAS G12C, with the primary activity of detecting tumours outside this area.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "5",
      "text": "Lumykras (Sotorasib) 5 M-DATS -020/4 [não pode ser tomado dia 1]; docetaxel: 75 mg/m2 IV, 21/21 dias; at e progress ão da fazer isso ou toxicidade inadequate ável. Permetrexedo é um Agente antineopl ásico antifolato com afinidade para vrios alvos enzyme áticos que ativa causando a disruption de processos metabólicos vitais folato-dependentes que são essenciais para a replica celular ão. Posologia: 500 mg/m2 IV, 21/21 dias; at e progress ão da fazer isso ou toxicidade inadequate ável.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "6",
      "text": "Lumykras (Sotorasib) 6 M-DATS -020/4 registo constituted a total of 13,243 patients with CPNPC, of whom 29,0% (n=3838) present a mutation in KRAS and 12,1% (n=1604), presenting specifically a mutation in KRAS p.G12C. Applying this value to carried out in Portugal, it is possible to conclude that, of the 4,603 cases of CPNPC diagnosed annually, 557 (12,1%) will be KRAS p.G12C positive. Using the national data of the Instituto Português de Oncologia do Porto Francisco Gentil, references to the period 2012 to 2016, 82,7% of the patients reported to the hospital were estimated to have made progress in CPC/IV.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "7",
      "text": "Lumykras (Sotorasib) 7 M-DATS -020/4 *Adenocarcinoma; ** Se histologia non predominantly escamosa; *** Tumors that express PD-L1 with a TPS ≥1% Termos de comparação1 Table 2: Termos de comparação1 Termos de comparação1 Medicamento em avaliação Sotorasib, 960 mg/dia PO, (oito comprimidos de 120 mg) once a day, at a progression ão da doença ou toxicidade inadequate. No trial CODE BREAK 200, no group doorasib, a median duration of the treatment of 19,86 (0,4, 101,3) have been administered over 7,0 (1, 34) weeks, and a relative intensity of the faith of 100%.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "8",
      "text": "LUMYKRAS (Sotorasib) 8 M-DATS -020/4 Medicamento comparador Docetaxel: 75 mg/m2 IV, 21/21 days; at progression ão da fazer isso ou toxicidade não aceitavel No trial CODE BREAK 200, no group do docetaxel, a mediana duration of treatment was 12,0 (3,0, 101,0) weeks administered in 4,0 (1, 33) cycles, e a relative intensity of dose was 94,8%.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "9",
      "text": "LUMYKRAS (Sotorasib) 9 M-DATS -020/4 4. Measures de évaluation de bienfait et dano e classification de son importance The measures de évaluation de bienfait et dano (measures de résultat) defined are found in Table 3. These result measures have been classified by degree of importance in critical and important, but not critical Table 3: Measures de résultat e classification de son importance Measures de evaluation Pontuação* Classification da importância das medidas* Measures de efficacia Surviência global 9 Critical Surviência livre de survivão 6 Important Taxa de resposta 5 Important Qualidade de vida 9 Critical adversidades de segurança Taxa de eventos 6 Important Taxa de eventos moris G3 - Taxa 4 7 Critical de abandono de fase de tratamentos por fase de avaliamento de dossiers médicos abertos, course of examination of the toxicity of drugs, course of examination of the toxicity of drugs, course of examination of the toxicity of drugs, course of examination of the toxicity of drugs, course of",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "10",
      "text": "LUMYKRAS (Sotorasib) 10 M-DATS -020/4 safety and data of the study of indirect comparison and of the essay CodeBreak 200 for analysis of comparative efficacy.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "11",
      "text": "For the efficacy indicators related to an exposure to treatment, Lumykras (Sotorasib) 11 M-DATS -020/4 was considered a population with at least one dose of treatment with sotorasib and with at least one lesson identified in the initial evaluation of the study.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "12",
      "text": "In relation to mortality related to medicines, no total of 20 (15,9%) patients reported that they led to their death. However, in none of the cases a causal relationship with the treatment was established. For a Tax on Abandonment for Toxicity were considered to be discontinued due to an emerging treatment, which occurred in 11 (8,7%) patients, but only 9 (7,1%) patients reported that they were treated with less than 57% of the total cases (32,5%, 1%, 1%, 3%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 2%, 1%, 1%, 2%, 1%, 2%, 1%, 2%, 2%, 1%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 2%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3%, 3",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "13",
      "text": "LUMYKRAS (Sotorasib) 13 M-DATS -020/4 Revisão sistemática da literatura e estudo de comparação indirecta3,4 Two RSLs were implemented with the aim of identifying all clinical trials evaluating therapeutic therapies approved in Europe and the United States (excluding therapeutic therapies directed at a change) in patients with CPNPC prior to KRAS G12C mutado previously treated.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "14",
      "text": "The flow of publications included and excluded from the systematic review of the 17 unique studies identified, eight of which will not include documentation as part of most of the treatments and new ones that do not present information necessary, in particular as curves of Kaplan-Meier na popula ção de interesse, to carry out an indirect comparison through the methodology of the MAIC.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "15",
      "text": "Similarly, a unique indirect comparison feasible in patients with advanced CPNPC KRAS or KRAS G12C mutated, previously treated, was a de sotorasib versus docetaxel, based on the results of the study CodeBreak 100 (sotarasib) and SELECT -1 (docetaxel).",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "16",
      "text": "Lumykras (Sotorasib) 16 M-DATS -020/4 On the basis of the analysis, the size of the effective sample (ESS) resulting from a total of 108,9, representing a median reduction of 14% compared to the original size of 126 patients. In relation to global survival, it was estimated that there was no risk of death of 39% (HR=0.611; IC 95%: 0.451; 0.829), which translates into an extension of the median survival time of 7,2 months (15,3 versus 8,1 months) (Figure 3). Figure 3.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "17",
      "text": "In the case of patients who have been treated for a drug or other substance, there is no evidence that the drug or other substance has been used to treat them. In the case of patients who have been treated for a drug or other substance, there is no evidence that the drug or other substance has been used to treat them.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "18",
      "text": "Lumykras (Sotorasib) 18 M-DATS -020/4 Estudo CodeBreaK 200: A Phase 3 Study to Compare AMG 510 with Docetaxel in NSCLC Subjects With KRAS p.G12C Mutati on5 Estudo de fase 3 en curso, multicéntrico, randomised, open, controlled actively to evaluate an efficacy, safety and tolerability of sotorasib versus docetaxel in patients with CPNC locally advanced and irrespective mutable or metastatic previously treated o, commution KRAS p.G12C confirmed centrally. The report presented by TAIM describes the results of the study following an initial analysis of the objective of PFS, when it occurs in approximately 230 of the PFS studies, or the continuous study of docetaxel in patients with PPNP, while the study continues to do so as to assess the progress of the study plan, including approximately 330 clinical or clinical centers of the study, as to the extent that it continues to do so.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "19",
      "text": "Lumykras (Sotorasib) 19 M-DATS -020/4 The evaluations of tumours were carried out during the study every 6 weeks from the 1st day to the 4th week of the first cycle, and subsequently, at intervals of 9 weeks until the central confirmation of the progression, the beginning of another anticancer therapy, the withdrawal of consent, the loss of follow-up or death, which occurred first.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "20",
      "text": "Lumykras (Sotorasib) 20 M-DATS -020/4 planned for the moment when a PFS was considered statistically significant, and the last randomized participant had had an opportunity to have at least 12 weeks of follow-up. For this reason the report presented does not include a final analysis, which will be carried out when the last part of the presentation has concluded a long-term follow-up. A total of 616 participants were selected for inclusion in this study, of these, 345 were included in randomized doses for sotorasib (171 individuals) or docetaxel (174 individuals).",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "21",
      "text": "The median for patients treated with docetaxel is 10.6 months (IC 95%: 8.9; 14.0) for patients treated with docetaxel is 11.3 months (IC 95%: 9.0: 14.9) for patients treated with docetaxel. HR for an OS treated with docetaxel is 1.010 days (IC 95%: 0.77; 1.33, p = 0.53) and was calculated independently to the existence of crossover therapy or subsequent treatment in the KRAS group p.G.C.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "22",
      "text": "The results of the study showed that all the relevant subgroups were analysed in a preliminary analysis of the progress of the book of life of the participants. The results of the study showed that all the subgroups were evaluated in a preliminary analysis of the progress of the book of life of the participants.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "23",
      "text": "Lumykras (Sotorasib) 23 M-DATS -020/4 Qualidade de Vida EORTC QLQ -C30 e EORTC QLQ -LC13 In terms of alteration from the beginning of the study until week 12 (MMRM analysis), as medias de alteração dos mínimos quadrados (LS) were 6,93 (IC 95%: 3,66; 10,19) for the state of global health, 8,78 (IC 95%: 5,39; 12,17) for a physical function, as medias de alteração (EP) do LS within the group were 0,03 (1,45) for the state of global health/QV, 0,10 (1,48) for a physical function e -0,57 (1,41) for a displacement (composta) in the suborasib e -6,90 (18) for the state of global health/QV, dos dos dos dos dos dos dos dos de saúde/QV -68 (1,62) for the functioning of a doctorate for a doctorate for a doctorate for a doctorate of physics (docs), 12,52 (1,58) for a doctorate for a doctorate for a doctorate for a doctorate",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "24",
      "text": "24 M-DATS -020/4 (DP = 18,2) for subcutaneous and docetaxel treatment respectively and is expected to have a better tolerability with subcutaneous treatment (cf. also evolution of the distribution of cumulative doses from the baseline level at a week 12. No group safety measures for subcutaneous treatment for a duration of 19,86 (0,4; 101,3) weeks administered over 7,0 (1, 34) cycles, and a relative intensity of the group dose of 100% (23,7; 100,0). No group dose of docetaxel, a duration of the treatment for 12,0 (3,0; 101,0) weeks over 4,0 (1, 33) cycles, and a relative intensity of the administered dose of 94,8% (48,56).",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "25",
      "text": "25 M-DATS -020/4 Taxa de eventos adversos G3 -4 Foram notified de eventos adversos de grau ≥3 de 121 doentes (71,6%) no group do sotorasib e 91 doentes (60,3%) no group do docetaxel, e as rates of events adjusted to exposure were of 177,4 and 271,2 respectively. Foram notified de eventos adversos related to the treatment of degree 3 de 56 doentes (33,1%) no group do sotorasib e 61 doentes (40,4%) no group do docetaxel, e as rates of events adversos to exposure were of 71,6 e 160,9 respectively. Taxa de eventos Umam de eventos total de doentes (98,2%) no group doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes doentes do",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "26",
      "text": "Similarly, the systematic evaluation only results from data that allow indirect comparison of Sotorasib with Docetaxel, since this analysis has been carried out via MAIC not anchored. Additionally, the data presented come from the interim analysis of an experimental randomized phase 3 in progress, randomized, open, controlled actively to evaluate an efficacy, safety and tolerability of Sotorasib versus Docetaxel in patients with CPNPC locally advanced and irressable or metastatic previously treated, with a confirmed KRAS mutation p.G12C centrally.",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "27",
      "text": "In view of the global safety data, the safety data showed an acceptable profile. No clinical trial faced with a III incidence of adverse events degree 3 - 4, serious adverse events and fatais foi superior no group treated by the laboratory. No, however, an ad hoc analysis of taxes of events adjusted to the exposure showed the best profile of the laboratory (71.6 vs 160.9). 7.",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "28",
      "text": "Lumykras (Sotorasib) 28 M-DATS -020/4 III that compares a therapeutic treatment with docetaxel and suborasib in an adult population with CPNPC advanced and previously treated with KRAS G12C mutated. There are no data that allow comparing sotorasib and any of the comparative alternatives indicated in the evaluation matrix, a exception of docetaxel. In terms of comparative fiction, the data from the interim analysis of the clinical trial of phase III indicate that the treatment with suborasib resulted in an improvement in survival of the progression book of 1.1 months and a 34% reduction in the probability of progression or mobility comparatively to docetaxel (HR 0.66% [9CI: 0.51, 0.86], - atrp002), evaluation of the progress of the docetaxel (24.8% vs. 21.5% of the state-of-the-art time), evaluation of the patient's progress (28.5% vs. 21.5% of the state-of-the-art time), evaluation of the patient's response (98.5% vs.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "29",
      "text": "• Sotorasib showed a safety profile similar to a docetaxel. • There are no data that allow comparing sotorasib with any of the other alternative therapies indicated in the evaluation matrix. 9.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "30",
      "text": "Lumykras (Sotorasib) 30 M-DATS -020/4 10. Non-applicable economic evaluation 11. Conclusions The medicinal product Lumykras (Sotorasib) was subject to a prior evaluation for the purposes of public financing for the treatment of patients with lung cancer of non-small cells (CPNPC) advanced with KRAS G12C mutated and which have progressed after, at least, a prior line of systemic therapy. In comparison with docetaxel, the medicinal product below has not demonstrated a therapeutic added value, because it was not financed by this indication.",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "31",
      "text": "Lumykras (Sotorasib) 31 M-DATS -020/4 12. Referências bibliográficas Grupo de Avaliação da Evidência. Relatório de Avaliação Farmacoterapêutico (sotorasib). INFARMED IP. Versão 1.0. de 03 de Abril de 2023 Amgen Inc., A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacocinetics, Pharmacodynamics, and Efficiency of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With P.G12C Mutation (CodeBreak 100) (data on file).",
      "start_page": 31,
      "end_page": 31
    }
  ]
}